Copyright ©2014 Baishideng Publishing Group Inc.
World J Hepatol. May 27, 2014; 6(5): 326-339
Published online May 27, 2014. doi: 10.4254/wjh.v6.i5.326
Figure 1
Figure 1 Hepatitis C virus RNA drop after lead-in phase (treatment week 4).
Figure 2
Figure 2 SVR rate after the lead-in period in patients with F3/4 fibrosis. PR: Conventional therapy (PEGylated interferon-α and ribavirin). ВOC RGT: Boceprevir-based, viral response-dependent triple therapy; BOC/PR48: Boceprevir-based triple therapy for 48 wk; the results are from the SPRINT-2 and RESPOND-2 studies.
Figure 3
Figure 3 Portion of patients treated either with TMC435 at 75 mg/d or 150 mg/d or with placebo, combined with PEGylated interferon/ribavirin, who reached SVR24 (%) in the PILLAR study[15].
Figure 4
Figure 4 Asunaprevir rate (%) after 12- and 24-wk follow-up in the AI447-011 study. ASV: Asunaprevir; DCV: Daclatasvir; PEG-IFN: PEG-IFNPEGylated interferon; RBV: Ribavirin.
Figure 5
Figure 5 Undetectable hepatitis C virus RNA rate depending on IL28B polymorphism.